1-(6-Chloro-pyrazin-2-YL)-4-ethylamino-piperidine-4-carboxylic acid amide | 913282-62-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(6-Chloro-pyrazin-2-YL)-4-ethylamino-piperidine-4-carboxylic acid amide
• 英文别名: 1-(6-chloropyrazin-2-yl)-4-(ethylamino)piperidine-4-carboxamide
• CAS: 913282-62-9
• 化学式: C₁₂H₁₈ClN₅O
• 分子量: 283.761
• InChiKey: JYXAGTRFGJZPPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  84.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(6-Chloro-pyrazin-2-YL)-4-ethylamino-piperidine-4-carboxylic acid amide 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 生成 1-(5-bromo-6-chloro-pyrazin-2-yl)-4-ethylamino-piperidine-4-carboxylic acid amide
  参考文献：
  名称：

  Aminopyrazine CB1 receptor inverse agonists

  摘要：

  A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential. Optimized compounds were demonstrated to be inverse agonists and compared in vivo with rimonabant for their ability to inhibit food intake, to occupy central CB1 receptors and to influence hormonal markers associated with obesity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.022
• 作为产物：
  描述：

  4-(乙氨基)-4-哌啶甲酰胺 、 2,6-二氯吡嗪 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 1-(6-Chloro-pyrazin-2-YL)-4-ethylamino-piperidine-4-carboxylic acid amide
  参考文献：
  名称：

  Aminopyrazine CB1 receptor inverse agonists

  摘要：

  A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential. Optimized compounds were demonstrated to be inverse agonists and compared in vivo with rimonabant for their ability to inhibit food intake, to occupy central CB1 receptors and to influence hormonal markers associated with obesity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.022

文献信息

• Substituted heteroaryl CB1 antagonists
  申请人：Yuan Jun

  公开号：US20070078135A1

  公开（公告）日：2007-04-05

  Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

  提供了公式I的化合物，其中变量如此处所述。这些化合物可用于在体内或体外调节CB1活性，并且在治疗对CB1调节敏感的人类、驯养的伴侣动物和家畜动物的食欲紊乱、肥胖和成瘾性疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究和各种体外测定的配体的使用方法。
• SUBTITUTED HETEROARYL CB1 ANTAGONISTS
  申请人：NEUROGEN CORPORATION

  公开号：EP1871762A2

  公开（公告）日：2008-01-02
• [EN] SUBTITUTED HETEROARYL CB1 ANTAGONISTS<br/>[FR] ANTAGONISTES CB1 HETEROARYLE SUBSTITUE
  申请人：NEUROGEN CORP

  公开号：WO2006113704A2

  公开（公告）日：2006-10-26

  [EN] Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CBl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CBl modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such Iigands for receptor localization studies and various in vitro assays.
  [FR] L'invention concerne des composés de formule (I). Dans ces formules, les variantes sont telles que décrites dans la description. Ces composés peuvent être utilisés afin de moduler l'activité in vivo ou in vitro de CB1, et sont particulièrement utiles dans le traitement de troubles réagissant à la modulation CB1 chez les humains, les animaux de compagnie domestiqués et le bétail, notamment les troubles de l'appétit, l'obésité et les troubles de dépendance. L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation de celles-ci afin de traiter ces troubles, ainsi que des procédés d'utilisation de ses ligands dans des études de localisation de récepteur et divers dosages in vitro.
• Aminopyrazine CB1 receptor inverse agonists
  作者：David J. Wustrow、George D. Maynard、Jun Yuan、He Zhao、Jianmin Mao、Qin Guo、Mark Kershaw、Jack Hammer、Robbin M. Brodbeck、Kristen E. Near、Dan Zhou、David S. Beers、Bertrand L. Chenard、James E. Krause、Alan J. Hutchison

  DOI：10.1016/j.bmcl.2008.04.022

  日期：2008.6

  A series of 5,6-diaryl-2-amino-pyrazines were prepared and found to have antagonist-like properties at the CB1 receptor. Subsequent SAR studies optimized both receptor potency and drug-like properties including solubility and Cytochrome-P450 inhibition potential. Optimized compounds were demonstrated to be inverse agonists and compared in vivo with rimonabant for their ability to inhibit food intake, to occupy central CB1 receptors and to influence hormonal markers associated with obesity. (C) 2008 Elsevier Ltd. All rights reserved.